IVBXF
Price
$11.50
Change
-$0.40 (-3.36%)
Updated
Jul 23 closing price
Capitalization
20.45B
ONC
Price
$294.52
Change
+$3.05 (+1.05%)
Updated
Jul 28, 04:59 PM (EDT)
Capitalization
33.73B
8 days until earnings call
Interact to see
Advertisement

IVBXF vs ONC

Header iconIVBXF vs ONC Comparison
Open Charts IVBXF vs ONCBanner chart's image
Innovent Biologics
Price$11.50
Change-$0.40 (-3.36%)
Volume$675
Capitalization20.45B
BeOne Medicines
Price$294.52
Change+$3.05 (+1.05%)
Volume$3.27K
Capitalization33.73B
IVBXF vs ONC Comparison Chart in %
Loading...
IVBXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IVBXF vs. ONC commentary
Jul 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IVBXF is a Hold and ONC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 29, 2025
Stock price -- (IVBXF: $12.07 vs. ONC: $294.51)
Brand notoriety: IVBXF and ONC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IVBXF: 108% vs. ONC: 113%
Market capitalization -- IVBXF: $20.45B vs. ONC: $33.73B
IVBXF [@Biotechnology] is valued at $20.45B. ONC’s [@Biotechnology] market capitalization is $33.73B. The market cap for tickers in the [@Biotechnology] industry ranges from $316.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IVBXF’s FA Score shows that 0 FA rating(s) are green whileONC’s FA Score has 0 green FA rating(s).

  • IVBXF’s FA Score: 0 green, 5 red.
  • ONC’s FA Score: 0 green, 5 red.
According to our system of comparison, both IVBXF and ONC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IVBXF’s TA Score shows that 2 TA indicator(s) are bullish while ONC’s TA Score has 5 bullish TA indicator(s).

  • IVBXF’s TA Score: 2 bullish, 5 bearish.
  • ONC’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ONC is a better buy in the short-term than IVBXF.

Price Growth

IVBXF (@Biotechnology) experienced а +0.58% price change this week, while ONC (@Biotechnology) price change was +0.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.28%. For the same industry, the average monthly price growth was +17.90%, and the average quarterly price growth was +45.83%.

Reported Earning Dates

ONC is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ONC($33.7B) has a higher market cap than IVBXF($20.4B). IVBXF YTD gains are higher at: 168.222 vs. ONC (59.445).
IVBXFONCIVBXF / ONC
Capitalization20.4B33.7B61%
EBITDAN/A-116.48M-
Gain YTD168.22259.445283%
P/E RatioN/AN/A-
RevenueN/A4.18B-
Total CashN/A2.52B-
Total DebtN/A997M-
FUNDAMENTALS RATINGS
IVBXF vs ONC: Fundamental Ratings
IVBXF
ONC
OUTLOOK RATING
1..100
9650
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
7071
SMR RATING
1..100
9693
PRICE GROWTH RATING
1..100
3541
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a46

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ONC's Valuation (60) in the Biotechnology industry is in the same range as IVBXF (64) in the null industry. This means that ONC’s stock grew similarly to IVBXF’s over the last 12 months.

IVBXF's Profit vs Risk Rating (70) in the null industry is in the same range as ONC (71) in the Biotechnology industry. This means that IVBXF’s stock grew similarly to ONC’s over the last 12 months.

ONC's SMR Rating (93) in the Biotechnology industry is in the same range as IVBXF (96) in the null industry. This means that ONC’s stock grew similarly to IVBXF’s over the last 12 months.

IVBXF's Price Growth Rating (35) in the null industry is in the same range as ONC (41) in the Biotechnology industry. This means that IVBXF’s stock grew similarly to ONC’s over the last 12 months.

IVBXF's P/E Growth Rating (100) in the null industry is in the same range as ONC (100) in the Biotechnology industry. This means that IVBXF’s stock grew similarly to ONC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IVBXFONC
RSI
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
61%
Bearish Trend 4 days ago
80%
Momentum
ODDS (%)
Bullish Trend 4 days ago
58%
Bullish Trend 4 days ago
69%
MACD
ODDS (%)
Bearish Trend 4 days ago
54%
Bullish Trend 4 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
61%
Bearish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
60%
Bullish Trend 4 days ago
73%
Advances
ODDS (%)
N/A
Bullish Trend 11 days ago
76%
Declines
ODDS (%)
Bearish Trend 6 days ago
60%
Bearish Trend 18 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
61%
Bearish Trend 4 days ago
75%
Aroon
ODDS (%)
Bullish Trend 4 days ago
63%
Bearish Trend 4 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
IVBXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QTEC218.531.37
+0.63%
First Trust NASDAQ-100-Tech Sector ETF
XOCT36.190.02
+0.06%
FT Vest US Eq Enh & Mod Buf ETF-Oct
SIXF30.35-0.05
-0.16%
AllianzIM US Lrg Cp 6M Bfr10 Feb/Aug ETF
VGSR10.45-0.16
-1.47%
Vert Global Sustainable Real Estate ETF
TGONF16.50-0.50
-2.94%
Tetragon Financial Group